MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for mnkd
5.54
+0.33 (6.33%)
After Hours: 5.52 -0.02 (-0.36%)
Jun 3, 7:24PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.22 - 5.55
52 week 3.46 - 11.48
Open 5.25
Vol / Avg. 8.74M/7.76M
Mkt cap 2.13B
P/E     -
Div/yield     -
EPS -0.44
Shares 409.58M
Beta 1.21
Inst. own 27%
Aug 10, 2015
Q2 2015 Mannkind Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Mannkind Corp at JMP Securities Life Sciences Conference - 9:30AM EDT - Add to calendar
Jun 10, 2015
Mannkind Corp at Goldman Sachs Healthcare Conference - 11:40AM EDT - Add to calendar
Jun 3, 2015
Mannkind Corp at Jefferies Global Healthcare Conference
May 21, 2015
Mannkind Corp Annual Shareholders Meeting
May 13, 2015
Mannkind Corp at Bank of America Merrill Lynch Health Care Conference
May 8, 2015
Q1 2015 Mannkind Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 Mannkind Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -32.60% -60.75%
Return on average equity - -
Employees 287 -
CDP Score - -

Address

28903 North Avenue Paine
VALENCIA, CA 91355
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The Company’s product candidate is AFREZZA which is an ultra rapid-acting insulin that is intended to improve glycemic control in adults with type 1 or type 2 diabetes. AFREZZA is absorbed into the bloodstream more quickly than subcutaneously injected rapid acting insulin analogs and regular human insulin. The time action profile of AFREZZA mimics the early phase insulin response observed in healthy normal individuals after a meal, which is characteristically absent in patients with type 2 diabetes. The Company’s subsidiaries are AlleCure and CTL.

Officers and directors

Alfred E. Mann Executive Chairman of the Board
Age: 89
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hakan S. Edstrom President, Chief Executive Officer, Chief Operating Officer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew Pfeffer CPA Chief Financial Officer, Vice President, IR Contact Officer
Age: 57
Bio & Compensation  - Reuters
Juergen A. Martens Ph.D. Corporate Vice President - Technical Operations, Chief Technical Officer
Age: 59
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Diane M. Palumbo Corporate Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent Kresa Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
James S. Shannon M.D. Director
Age: 59
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael A. Friedman M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters